New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
12:25 EDTAMGNAmgen: Phase 3 EVOLVE trial results presented
Amgen announced results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar®/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular, CV, events among 3,883 patients with secondary hyperparathyroidism, HPT, and chronic kidney disease, CKD, receiving dialysis. The primary endpoint of the study was time to the composite event comprising all-cause mortality or first non-fatal CV event, including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event. Although patients in the Sensipar/Mimpara arm experienced a seven percent reduction in the primary endpoint (Hazard Ratio 0.93, 95 percent CI 0.85 to 1.02, p=0.112), the results were not statistically significant, and the trial did not meet its primary endpoint in the intent-to-treat analysis. These data were published today in the New England Journal of Medicine and simultaneously presented at the American Society of Nephrology's Kidney Week.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
13:56 EDTAMGNAmgen sell-off creates buying opportunity, says Argus
After Amgen reported weaker than expected Q1 results, Argus believes that the company's key growth drivers performed well last quarter. The firm thinks the company's growth outlook looks solid, and it keeps a Buy rating on the shares.
09:34 EDTAMGNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD NFLX TSLA VZ MU WFM AMGN
09:16 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAMGNAmgen weakness a buying opportunity, says Cowen
Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.
06:54 EDTAMGNCambridge Healthtech Institute to hold a conference
Subscribe for More Information
06:53 EDTAMGNFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 22, 2014
16:32 EDTAMGNAmgen says total product sales declined 9% sequentially in Q1
Subscribe for More Information
16:25 EDTAMGNAmgen trades lower after results, first look
Subscribe for More Information
16:06 EDTAMGNAmgen sees FY14 EPS $7.90-$8.20, consensus $8.16
Subscribe for More Information
16:05 EDTAMGNAmgen reports Q1 EPS $1.87, consensus $1.94
Subscribe for More Information
15:32 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
14:35 EDTAMGNEarnings Preview: Amgen's timeline for Evolocumab will be in focus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use